Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Clinical Benefit of WP-REP1 to Treat the Inherited Retinal Disease (IRD) Choroideremia

Next Previous
Search
Trial Profile

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Clinical Benefit of WP-REP1 to Treat the Inherited Retinal Disease (IRD) Choroideremia

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WP REP1 (Primary)
  • Indications Choroideraemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mawson Infrastructure Group

    • Most Recent Events

    • 13 Sep 2019 New trial record
    • 09 Sep 2019 According to a Wize Pharma media release, as per the Exclusive License Agreement, at the closing, Copernicus will provide development services to Wize with the aim to complete this trial.In consideration for the development services, Wize agreed to pay Copernicus amounts over time to fund and execute the workplan leading to the completion of this trial.
    • 09 Sep 2019 According to a Wize Pharma media release, the company has entered into an Exclusive License Agreement with Copernicus Therapeutics, Inc., pursuant to which, at the closing, it will be granted exclusive rights to license, develop and commercialize products based on a non-viral gene therapy technology developed by Copernicus for the treatment of Choroideremia (CHM).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top